ANAT inhibitor-1, targeting Arylalkylamine N-Acetyltransferase (AANAT), is primarily used in research settings to study the enzyme's role in biological processes, particularly melatonin synthesis from serotonin in the pineal gland. This inhibition helps investigate pathways involved in circadian rhythms, sleep regulation, and neurotransmitter modulation. By blocking AANAT activity, researchers gain insights into its impact on neurological and sleep-related conditions, such as depression, anxiety, sleep disorders, and potentially Parkinson's disease through neuroprotective mechanisms. It is also employed in pharmacological studies to examine enzyme-compound interactions, supporting drug discovery for melatonin-related imbalances. Applications are mainly in laboratory and preclinical studies to elucidate complex biochemical pathways.